Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote Sells 4,387 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTXGet Free Report) SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at $972,921.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $12.24 on Thursday. The company has a market capitalization of $936.24 million, a price-to-earnings ratio of -5.83 and a beta of 0.71. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $14.07. The stock has a fifty day simple moving average of $9.48 and a 200 day simple moving average of $7.92. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTXGet Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million during the quarter, compared to analyst estimates of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. Sell-side analysts expect that Travere Therapeutics, Inc. will post -3.96 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Barclays upped their target price on Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Guggenheim upgraded shares of Travere Therapeutics from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a report on Monday. Citigroup upped their price target on shares of Travere Therapeutics from $14.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Bank of America upped their price target on shares of Travere Therapeutics from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Finally, HC Wainwright upped their price target on shares of Travere Therapeutics from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Read Our Latest Report on Travere Therapeutics

Institutional Trading of Travere Therapeutics

Institutional investors have recently bought and sold shares of the company. EntryPoint Capital LLC bought a new stake in Travere Therapeutics during the first quarter valued at $32,000. DRW Securities LLC bought a new stake in Travere Therapeutics during the second quarter valued at $95,000. Forefront Analytics LLC boosted its position in Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after acquiring an additional 1,237 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Travere Therapeutics by 68.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock valued at $113,000 after acquiring an additional 5,962 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in Travere Therapeutics during the second quarter valued at $117,000.

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Featured Stories

Insider Buying and Selling by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.